Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3804270 | 0.93 | KMT2A (0.48) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL3686829 | 0.92 | KMT2A (0.50) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL3694189 | 0.92 | KMT2A (0.47) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL3688122 | 0.90 | KMT2A (0.42) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL3807653 | 0.89 | KMT2A (0.51) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL367250 | 0.89 | KMT2A (0.55) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL3693640 | 0.85 | KMT2A (0.45) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL3691170 | 0.84 | KMT2A (0.53) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL17191295 | 0.83 | KMT2A (0.50) | KMT2AHPGDMEN1NPSR1HTT | |
| SCHEMBL3689656 | 0.83 | KMT2A (0.40) | KMT2AHPGDMEN1NPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357577-B2 | Bacterial nitroreductase enzymes and methods relating thereto | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-07-23 | — | — | US | disclosed |
| US-20180148463-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2018-05-31 | — | — | US | disclosed |
| US-9873710-B2 | Prodrugs and methods of use thereof | HEALTH INNOVATION VENTURES B.V. (NL) | 2018-01-23 | — | — | US | disclosed |
| US-20170044191-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044191-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2017-02-16 | — | — | US | disclosed |
| US-9505791-B2 | Prodrugs and methods of use thereof | HEALTH INNOVATION VENTURES B.V. (NL) | 2016-11-29 | — | — | US | disclosed |
| US-9505791-B2 | Prodrugs and methods of use thereof | HEALTH INNOVATION VENTURES B.V. (NL) | 2016-11-29 | — | — | US | disclosed |
| US-20150299230-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2015-10-22 | — | — | US | disclosed |
| US-20150299230-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2015-10-22 | — | — | US | disclosed |
| US-20130295011-A1 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | VICTORIA LINK LIMITED (NZ) | 2013-11-07 | — | — | US | disclosed |
| EP-2593796-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | Auckland Uniservices Limited (NZ) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012008860-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-01-19 | — | — | WO | disclosed |
| WO-2010044685-A1 | NITROPHENYL MUSTARD ALCOHOLS, THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148463-A1 | Novel Prodrugs And Methods Of Use Thereof | AKR1C3, AKR1C2, AKR1B1 | KMT2A 2224/4885HPGD 305/4885MEN1 2708/4885 |
| US-20150299230-A1 | Novel Prodrugs And Methods Of Use Thereof | AKR1C3, AKR1C2, AKR1B1 | KMT2A 2224/4885HPGD 305/4885MEN1 2708/4885 |
| US-20170044191-A1 | Novel Prodrugs And Methods Of Use Thereof | AKR1C3, AKR1C2, AKR1B1 | KMT2A 2224/4885HPGD 305/4885MEN1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.